Related Experiment Video
Updated: Jun 19, 2026
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma
K Janetzko1, K Hinz, S Marschner
1Institute of Transfusion Medicine and Immunology, Red Cross Blood Service Baden-Württemberg - Hessen, Heidelberg University, Medical Faculty of Mannheim, Germany. k.janetzko@blutspende.de
Background And Objectives:
Mirasol pathogen reduction technology (PRT) for platelet concentrates uses riboflavin and ultraviolet light. Previously, we described increased metabolism and activation for PRT platelets stored in 100% plasma. To improve platelet quality, we resuspended platelets in a mixture of plasma and platelet additive solution (PAS).
Materials And Methods:
Single-donor platelets were resuspended in plasma and split into an untreated control and a PRT-treated single product. One hundred and fifty millilitre PAS (SSP+) was added to both. Over 7 days, we assayed pH, glucose consumption-, lactate production rate and CD62p with and without TRAP.
Results:
On day 5, PRT units showed a significantly lower pH (7.087 +/- 0.105 vs. 7.288 +/- 0.200) accompanied by a higher lactate production (0.104 +/- 0014 vs. 0.063 +/- 0.017 mmol/10(12)/h) and glucose consumption rate (0.039 +/- 0005 vs. 0.028 +/- 0.009 mmol/10(12) platelets/h). CD62p expression was higher in treated units (44.5 +/- 13.0 vs. 16.5 +/- 7.6%).
Conclusion:
In comparison to PRT platelets resuspended in 100% plasma, a mixture of plasma and PAS improves pH and platelet metabolism but not platelet activation. Prolonged shelf-life for up to 7 days may be possible
Insights
Resuspending Mirasol pathogen reduction technology (PRT) platelets in a plasma and platelet additive solution (PAS) mixture improves pH and metabolism. This method enhances platelet quality and may extend shelf-life up to 7 days.
Area of Science:
- Blood banking and transfusion medicine
- Biotechnology and medical devices
- Hematology
Background:
- Mirasol pathogen reduction technology (PRT) utilizes riboflavin and UV light for platelet concentrates.
- Previous studies indicated increased metabolism and activation in PRT platelets stored in 100% plasma.
- Platelet quality is a critical factor in transfusion efficacy.
Purpose of the Study:
- To evaluate the impact of resuspending PRT platelets in a plasma and platelet additive solution (PAS) mixture on platelet quality.
- To compare the metabolic profile and activation markers of PRT platelets in PAS versus 100% plasma.
- To assess the potential for extended shelf-life of PRT platelets under the new storage conditions.
Main Methods:
- Platelet concentrates underwent Mirasol PRT treatment.
- Platelets were resuspended in either 100% plasma (control) or a mixture of plasma and PAS (SSP+).
- Assays included pH, glucose consumption, lactate production rate, and CD62p expression over 7 days.
Main Results:
- On day 5, PRT platelets in plasma/PAS showed significantly lower pH (7.087 vs. 7.288).
- Higher lactate production (0.104 vs. 0.063 mmol/10(12)/h) and glucose consumption (0.039 vs. 0.028 mmol/10(12) platelets/h) were observed in the plasma/PAS group.
- CD62p expression was higher in PRT units (44.5% vs. 16.5%), indicating increased platelet activation.
Conclusions:
- Resuspending PRT platelets in a plasma and PAS mixture improves pH and metabolic parameters compared to 100% plasma.
- Platelet activation was not improved by the plasma/PAS mixture.
- This approach may enable a prolonged shelf-life for PRT-treated platelet concentrates up to 7 days.
